ElsaLys Biotech grabs MABLife’s dual-acting antibody to treat cancer

06/07/2015 - 2 minutes

French ElsaLys Biotech just acquired MABLife’s anti-CD160 antibody. Originally developed for the treatment of vascular eye diseases, the antibody also has the potential to be applied for tumor therapy. It inhibits vascular proliferation and modulates the immune system.

To proliferate and migrate through the body, tumors rely on oxygen and nutrients supplies. Cancer cells initiate the formation of new blood vessels that will provide the required supply of nourishment. Therefore, angiogenesis inhibitors are popular targets for any cancer treatment.

The regulation of angiogenesis includes the receptor CD160 that is highly expressed on the surface of activated endothelial cells. Once activated by its natural ligand, the receptor provokes the death of new blood vessels.

An anti-CD160 antibody from MABLife, originally developed for ophthalmology, acts as an agonist to the ligand of the CD160 receptor. A big advantage of this ‘first-in-class’ antibody is that CD160 is only expressed in recent blood vessels and, hence, selectively triggers their death, whereas already existing vessels remain safe and sound. Furthermore, the receptor plays an important role in the modulation of Natural Killer cell and T-cell subpopulations.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member